TNSN01132A1 - Derives de pyrazole nouveaux et compositions les contenant. - Google Patents

Derives de pyrazole nouveaux et compositions les contenant.

Info

Publication number
TNSN01132A1
TNSN01132A1 TNTNSN01132A TNSN01132A TNSN01132A1 TN SN01132 A1 TNSN01132 A1 TN SN01132A1 TN TNSN01132 A TNTNSN01132 A TN TNSN01132A TN SN01132 A TNSN01132 A TN SN01132A TN SN01132 A1 TNSN01132 A1 TN SN01132A1
Authority
TN
Tunisia
Prior art keywords
compositions containing
pyrazole derivatives
novel pyrazole
diseases
compounds
Prior art date
Application number
TNTNSN01132A
Other languages
English (en)
Inventor
Blair Cooper Christopher
John Helal Christopher
Allen Sanner Mark
T Wager Travis
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of TNSN01132A1 publication Critical patent/TNSN01132A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'INVENTION CONCERNE DES COMPOSES DE FORMULE 1 DANS LAQUELLE R1, R2, R3 ET R4 REPRESENTENT DIVERS RADICAUX. ELLE CONCERNE EGALEMENT DES COMPOSITIONS PHARMACEUTIQUES LES CONTENANT. APPLICATION : UTILISATION DE CES COMPOSES ET COMPOSITIONS POUR LE TRAITEMENT ET LA PREVENTION DE MALADIES COMPORTANT UNE CROISSANCE CELLULAIRE ANORMALE, DE MALADIES NEURODEGENERATIVES ET DE DIVERSES AUTRES MALADIES.
TNTNSN01132A 2000-08-31 2001-08-30 Derives de pyrazole nouveaux et compositions les contenant. TNSN01132A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22941500P 2000-08-31 2000-08-31

Publications (1)

Publication Number Publication Date
TNSN01132A1 true TNSN01132A1 (fr) 2005-11-10

Family

ID=22861151

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN01132A TNSN01132A1 (fr) 2000-08-31 2001-08-30 Derives de pyrazole nouveaux et compositions les contenant.

Country Status (38)

Country Link
EP (1) EP1313710A1 (fr)
JP (1) JP2004507526A (fr)
KR (1) KR20030027093A (fr)
CN (1) CN1518543A (fr)
AP (1) AP2001002266A0 (fr)
AR (1) AR035345A1 (fr)
AU (1) AU2001280009A1 (fr)
BG (1) BG107455A (fr)
BR (1) BR0113574A (fr)
CA (1) CA2420363A1 (fr)
CR (1) CR6881A (fr)
CZ (1) CZ2003468A3 (fr)
DO (1) DOP2001000243A (fr)
DZ (1) DZ3398A1 (fr)
EA (1) EA200300205A1 (fr)
EC (1) ECSP034480A (fr)
EE (1) EE200300085A (fr)
GT (1) GT200100179A (fr)
HN (1) HN2001000192A (fr)
HR (1) HRP20030140A2 (fr)
HU (1) HUP0302669A3 (fr)
IL (1) IL154016A0 (fr)
IS (1) IS6687A (fr)
MA (1) MA26946A1 (fr)
MX (1) MXPA03001785A (fr)
NO (1) NO20030958L (fr)
NZ (1) NZ523656A (fr)
OA (1) OA12368A (fr)
PA (1) PA8528101A1 (fr)
PE (1) PE20020470A1 (fr)
PL (1) PL360742A1 (fr)
SK (1) SK2002003A3 (fr)
SV (1) SV2002000618A (fr)
TN (1) TNSN01132A1 (fr)
UY (1) UY26909A1 (fr)
WO (1) WO2002018346A1 (fr)
YU (1) YU14703A (fr)
ZA (1) ZA200301064B (fr)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1158985B1 (fr) 1999-01-13 2011-12-28 Bayer HealthCare LLC DIPHENYLE UREES A SUBSTITUTION OMEGA-CARBOXY ARYLE EN TANT QU'INHIBITEURS DE LA KINASE p38
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US6610677B2 (en) 2000-09-15 2003-08-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6613776B2 (en) 2000-09-15 2003-09-02 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
CA2422367C (fr) 2000-09-15 2010-05-18 Vertex Pharmaceuticals Incorporated Composes de pyrazole pouvant etre utilises comme inhibiteurs de la proteine kinase
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
KR100947185B1 (ko) 2000-12-21 2010-03-15 버텍스 파마슈티칼스 인코포레이티드 단백질 키나제 억제제로서 유용한 피라졸 화합물 및 이를 포함하는 조성물
ATE372114T1 (de) * 2001-09-27 2007-09-15 Applied Research Systems Verfahren zur erhöhung des testosteronspiegels
US20030216396A1 (en) 2002-02-11 2003-11-20 Bayer Corporation Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors
PT1478358E (pt) 2002-02-11 2013-09-11 Bayer Healthcare Llc Tosilato de sorafenib para o tratamento de doenças caracterizadas por angiogénese anormal
MXPA05000629A (es) * 2002-07-17 2005-04-25 Pharmacia Italia Spa Derivados de pirazol heterobiciclico como inhibidores de cinasa.
CA2501799C (fr) 2002-10-09 2008-06-17 Pfizer Products Inc. Composes pyrazole pour le traitement de maladies neurodegeneratives
EP1551842A1 (fr) * 2002-10-15 2005-07-13 Smithkline Beecham Corporation Composes de pyradazine utiles comme inhibiteurs de gsk-3
DE602004016964D1 (de) * 2003-02-27 2008-11-20 Smithkline Beecham Corp Neue verbindungen
JP2007511203A (ja) 2003-05-20 2007-05-10 バイエル、ファーマシューテイカルズ、コーポレイション キナーゼ阻害活性を有するジアリール尿素
JP4220548B2 (ja) * 2003-06-05 2009-02-04 エラン ファーマシューティカルズ，インコーポレイテッド アシル化されたアミノ酸・アミジルピラゾール、および関連化合物
PL1651612T3 (pl) 2003-07-22 2012-09-28 Astex Therapeutics Ltd Związki 3,4-pochodne 1h-pirazolu i ich zastosowanie jako kinazy zależne od cyklin (cdk) i modulatory kinazy syntazy glikogenu-3 (gsk-3)
DE602004010407T2 (de) 2003-07-23 2008-10-16 Bayer Pharmaceuticals Corp., West Haven Fluorsubstituierter omega-carboxyaryldiphenylharnstoff zur behandlung und prävention von krankheiten und leiden
BRPI0412820A (pt) * 2003-07-25 2006-09-26 Pfizer compostos de aminopirazol e utilização como inibidores de chk1
ES2347152T3 (es) * 2003-11-26 2010-10-26 Pfizer Products Inc. Derivados de aminopirazol como inhibidores de gsk-3.
US7244757B2 (en) 2004-04-01 2007-07-17 Pfizer Inc Pyrazole-amine compounds for the treatment of neurodegenerative disorders
WO2005103010A2 (fr) * 2004-04-21 2005-11-03 Astrazeneca Ab Composes chimiques
ATE517885T1 (de) 2004-04-30 2011-08-15 Bayer Healthcare Llc Substituierte pyrazolyl-harnstoff-derivate zur behandlung von krebs
US7498342B2 (en) 2004-06-17 2009-03-03 Plexxikon, Inc. Compounds modulating c-kit activity
EP1781637A1 (fr) * 2004-06-29 2007-05-09 Rigel Pharmaceuticals, Inc. Composés de quinoléine de substitution et leurs utilisations comme inhibiteurs de la cascade de signalement du récepteur d'immunoglobuline (ige)
US7491720B2 (en) 2004-10-29 2009-02-17 Banyu Pharmaceutical Co., Ltd. Aminopyridine derivatives having Aurora A selective inhibitory action
CA2587427A1 (fr) 2004-11-17 2006-05-26 Miikana Therapeutics, Inc. Inhibiteurs de kinase
AR054425A1 (es) 2005-01-21 2007-06-27 Astex Therapeutics Ltd Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
US8404718B2 (en) 2005-01-21 2013-03-26 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors
ES2375735T3 (es) 2005-02-04 2012-03-05 Astrazeneca Ab Derivados de pirazolilaminopiridina útiles como inhibidores de quinasas.
WO2006085685A1 (fr) * 2005-02-09 2006-08-17 Takeda Pharmaceutical Company Limited Dérivé de pyrazole
ES2308731T3 (es) 2005-02-16 2008-12-01 Astrazeneca Ab Compuestos quimicos.
US20080287437A1 (en) 2005-05-16 2008-11-20 Astrazeneca Ab Pyrazolylaminopyrimidine Derivatives Useful as Tyrosine Kinase Inhibitors
EP1741708A1 (fr) * 2005-06-28 2007-01-10 Sanofi-Aventis Deutschland GmbH Amides heterocycliques substitués contenant un linker cyclique ou insaturé, et leur utilisation comme agent pharmaceutique
EP2258359A3 (fr) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenèse par modulation des récepteurs muscariniques avec sabcomeline
US7678363B2 (en) 2005-08-26 2010-03-16 Braincells Inc Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs
KR101487027B1 (ko) 2005-09-30 2015-01-28 미카나 테라퓨틱스, 인크. 치환된 피라졸 화합물
EP1940389A2 (fr) 2005-10-21 2008-07-09 Braincells, Inc. Modulation de la neurogenese par inhibition de la pde
PT1945631E (pt) 2005-10-28 2012-10-15 Astrazeneca Ab Derivados de 4-(3-aminopirazole)pirimidina para utilização como inibidores da tirosina-cinase no tratamento do cancro
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
WO2007056221A2 (fr) 2005-11-03 2007-05-18 Vertex Pharmaceuticals Incorporated Aminopyrimidines utiles en tant qu'inhibiteurs de kinases
US7572809B2 (en) * 2005-12-19 2009-08-11 Hoffmann-La Roche Inc. Isoquinoline aminopyrazole derivatives
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2021000A2 (fr) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenèse par modulation de l'angiotensine
WO2008047364A2 (fr) * 2006-10-18 2008-04-24 Periness Ltd. Composition pharmaceutique destinée au diagnostic et au traitement de l'hypofertilité masculine
RU2009119181A (ru) 2006-10-21 2010-11-27 Эбботт Гмбх Унд Ко.Кг (De) Гетероциклические соединения и их применение в качестве ингибиторов гликогенсинтаза-киназы-3
WO2008063888A2 (fr) 2006-11-22 2008-05-29 Plexxikon, Inc. Composés modulant l'activité de c-fms et/ou de c-kit et utilisations associées
US7737149B2 (en) * 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
WO2008090114A1 (fr) 2007-01-24 2008-07-31 Glaxo Group Limited Compositions pharmaceutiques contenant du 2-méthoxy-5- (5-trifluorométhyl-tétrazol-i-yl-benzyl) - (2s-phényl-pipéridin-3s-yl-)
WO2009012283A1 (fr) 2007-07-17 2009-01-22 Plexxikon Inc. Composés et procédés pour la modulation des kinases et leurs indications
WO2009017453A1 (fr) * 2007-07-30 2009-02-05 Astrazeneca Ab Nouvelle combinaison thérapeutique d'antipsychotique et d'inhibiteur de gsk3 958
UA101166C2 (ru) 2007-09-21 2013-03-11 Аррей Биофарма Инк. Производные пиридин-2-иламино-1,2,4-тиадиазола как активаторы глюкокиназы для лечения сахарного диабета
JPWO2009130900A1 (ja) * 2008-04-24 2011-08-11 日本曹達株式会社 オキシム誘導体、中間体化合物および植物病害防除剤
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
SG173178A1 (en) 2009-04-03 2011-09-29 Hoffmann La Roche Propane- i-sulfonic acid {3- [5- (4 -chloro-phenyl) -1h-pyrrolo [2, 3-b] pyridine-3-carbonyl] -2, 4-difluoro-pheny l } -amide compositions and uses thereof
US20110081316A1 (en) * 2009-10-02 2011-04-07 Vertex Pharmaceuticals Incorporated Pyrazole inhibitors of phosphatidylinositol 3-kinase
NZ629615A (en) 2009-11-06 2016-01-29 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
CN103119035B (zh) 2010-09-27 2015-09-30 雅培股份有限两合公司 杂环化合物和它们作为糖原合成酶激酶-3抑制剂的用途
US9090592B2 (en) 2010-12-30 2015-07-28 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
EA028821B9 (ru) 2011-02-07 2018-10-31 Плексксикон, Инк. Соединения и способы для модуляции киназ, а также показания к их применению
TWI558702B (zh) 2011-02-21 2016-11-21 普雷辛肯公司 醫藥活性物質的固態形式
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
JP6545681B2 (ja) * 2013-08-16 2019-07-17 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ ３−置換シクロペンチルアミン誘導体
CN106580986B (zh) * 2016-11-28 2017-09-15 王保亮 一种治疗少弱精子症的药物组合物
WO2020142559A1 (fr) 2018-12-31 2020-07-09 Biomea Fusion, Llc Inhibiteurs de l'interaction ménine-mll
SG11202106304RA (en) 2018-12-31 2021-07-29 Biomea Fusion Llc Irreversible inhibitors of menin-mll interaction
CA3128155C (fr) * 2019-01-31 2023-09-19 Pfizer Inc. Composes 3-carbonylamino-5-cyclopentyl-1h-pyrazole ayant une activite inhibitrice sur cdk2
TW202229268A (zh) * 2020-12-22 2022-08-01 大陸商上海拓界生物醫藥科技有限公司 Ｃｄｋ２抑制劑及其製備方法
AU2022301047A1 (en) 2021-06-28 2024-01-04 Blueprint Medicines Corporation Cdk2 inhibitors
WO2023274397A1 (fr) * 2021-07-01 2023-01-05 上海拓界生物医药科技有限公司 Inhibiteur de cdk2, son procédé de préparation et son utilisation
TW202325280A (zh) * 2021-11-09 2023-07-01 大陸商上海拓界生物醫藥科技有限公司 一種胺基吡唑衍生物及其製備方法和用途
WO2023092088A1 (fr) * 2021-11-19 2023-05-25 Blueprint Medicines Corporation Inhibiteurs de cdk2 et leurs procédés de fabrication et d'utilisation
WO2023239629A1 (fr) * 2022-06-06 2023-12-14 Plexium, Inc. Composés et compositions pharmaceutiques qui dégradent cdk2

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4437270B2 (ja) * 1997-12-22 2010-03-24 バイエル コーポレイション 置換複素環式尿素を用いたｒａｆキナーゼの阻害
KR100579792B1 (ko) * 1998-05-13 2006-05-12 동화약품공업주식회사 신규 2,5-피리딘디카복실산 유도체
GB9811427D0 (en) * 1998-05-29 1998-07-22 Zeneca Ltd Chemical compounds
AU6314900A (en) * 1999-07-26 2001-02-13 Banyu Pharmaceutical Co., Ltd. Biarylurea derivatives
CN1373662A (zh) * 1999-08-12 2002-10-09 法玛西雅意大利公司 3(5)－氨基－吡唑衍生物、其制备方法及其用作抗肿瘤剂的用途
US6387900B1 (en) * 1999-08-12 2002-05-14 Pharmacia & Upjohn S.P.A. 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents
ES2253266T3 (es) * 1999-11-30 2006-06-01 Pfizer Products Inc. Compuestos de 2,4-diaminopirimidina utiles como inmunosupresores.
WO2001079198A1 (fr) * 2000-04-18 2001-10-25 Agouron Pharmaceuticals, Inc. Pyrazoles permettant d'inhiber des proteines kinases

Also Published As

Publication number Publication date
KR20030027093A (ko) 2003-04-03
ECSP034480A (es) 2003-03-31
EE200300085A (et) 2004-12-15
PL360742A1 (en) 2004-09-20
CA2420363A1 (fr) 2002-03-07
NO20030958D0 (no) 2003-02-28
IL154016A0 (en) 2003-07-31
EA200300205A1 (ru) 2003-06-26
HRP20030140A2 (en) 2003-04-30
BG107455A (en) 2003-09-30
HUP0302669A2 (hu) 2003-12-29
YU14703A (sh) 2006-05-25
HN2001000192A (es) 2001-08-28
IS6687A (is) 2003-01-16
CN1518543A (zh) 2004-08-04
NZ523656A (en) 2004-11-26
CZ2003468A3 (cs) 2004-05-12
EP1313710A1 (fr) 2003-05-28
BR0113574A (pt) 2003-07-22
DOP2001000243A (es) 2002-10-15
AR035345A1 (es) 2004-05-12
SK2002003A3 (en) 2004-04-06
CR6881A (es) 2004-03-11
NO20030958L (no) 2003-02-28
MA26946A1 (fr) 2004-12-20
GT200100179A (es) 2002-04-22
PA8528101A1 (es) 2002-07-30
WO2002018346A1 (fr) 2002-03-07
ZA200301064B (en) 2004-04-19
DZ3398A1 (fr) 2002-03-07
MXPA03001785A (es) 2003-06-04
AP2001002266A0 (en) 2001-09-30
UY26909A1 (es) 2002-03-22
HUP0302669A3 (en) 2004-03-29
PE20020470A1 (es) 2002-06-18
SV2002000618A (es) 2002-10-24
JP2004507526A (ja) 2004-03-11
AU2001280009A1 (en) 2002-03-13
OA12368A (en) 2004-04-13

Similar Documents

Publication Publication Date Title
TNSN01132A1 (fr) Derives de pyrazole nouveaux et compositions les contenant.
TNSN99252A1 (fr) Composes nouveaux modulateurs de chimiokine ccr5 et compositions pharmaceutiques les contenant.
TNSN01048A1 (fr) Acides malonamiques et leurs derives, et compositions les contenant
TNSN01114A1 (fr) Derives d'imidazole nouveaux et compositions les contenant
TNSN99236A1 (fr) Derives bicycliques substitues nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN99155A1 (fr) 1-aryl-3-arylmethyl-1,8-naphtyridine-4(1h)-ones nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN97198A1 (fr) Derives de 6-phenylpyridyl-2- amine et compositions pharmaceutiques les contenant
TNSN99170A1 (fr) Derives de tetrahydroquinoleine substitues nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99162A1 (fr) Derives de quinoleine-2-one a substituant alcynyle nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN98238A1 (fr) Macrolides nouveaux
TNSN00028A1 (fr) Derives de quinoleine -2-one a substituant heteroaryle nouveaux procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN98084A1 (fr) Derives de macrolides substitues en position c-4
TNSN98017A1 (fr) Derives de sulfonyluree, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN99106A1 (fr) Derives d'isothiazole nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN00228A1 (fr) Derives de benzimidazole nouveaux, et compositions les contenant
TNSN99156A1 (fr) Derives d'acide hydroxypipecolate-hydroxamique nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN01102A1 (fr) Derives de pyrazole nouveaux, procede pour leur preparation et compositions les contenant.
TNSN01019A1 (fr) Pyrimidinecarboxamides utiles comme inhibiteurs d'iso-ezymes pde4, et compositions les contenant
TNSN98082A1 (fr) DERIVES SUBSTITUES EN C - 4 DE 9 - DESOXO - 9a - aza - 9a HOMOERYTHROMYCINE A.
TNSN01091A1 (fr) Derives bicycliques nouveaux, compositions les contenant et leur utilisation pour le traitement d'une croissance cellulaire anormale
TNSN00191A1 (fr) Composes nouveaux, compositions les contenant et leur utilisation dans le traitement d'une ischemie
TNSN00036A1 (fr) Acides oxamiques nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN01124A1 (fr) Derives de 1,4-dihydropyridine nouveaux , servant d'antagonistes de la bradykinine, et compositions les contenant
TNSN98203A1 (fr) Derives de thienopyrimidine et tienopyridine utiles comme agents anticancereux, et compositions les contenant
TNSN99172A1 (fr) 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant